{"entity":{"id":"nct04685226","kind":"trial","name":"A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of ICP-723 in advanced solid tumours, run by Beijing InnoCare Pharma Tech Co., Ltd., now recruiting.","summary":"A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04685226 by Beijing InnoCare Pharma Tech Co., Ltd., with 310 participants planned, started 2020-09-27 and due to reach its primary completion in 2028-01-25. Interventions recorded: ICP-723.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04685226","url":"https://clinicaltrials.gov/study/NCT04685226"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04685226","phase":"1/2","setting":"A Multicenter, Nonrandomized, Open-Label Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Solid Tumors","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","enrolled":310,"outcomes":[]},"route":"/trials/nct04685226/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}